JH-013

N/A

Report date: 2025/01/22 10:49:22

Base Information

Drug NameJH-013
Drug Alias NameJH-013
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionB-cell activating factor receptor inhibitors
TargetsB-cell activating factor receptor
Therapy Area/IndicationsLupus Erythematosus, SystemicSjogren's SyndromeArthritis, Rheumatoid +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBiotech Pharmaceuticals Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBiotech Pharmaceutical Co LtdAmbotec Pharmaceutical Co LtdBiotech Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicSjogren's SyndromeArthritis, Rheumatoid +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A